Skip to main content
Premium Trial:

Request an Annual Quote

GenMark Receives CE Mark for Fungal Panel, Reports Q1 Preliminary Revenues Up 13 Percent

NEW YORK (GenomeWeb) – GenMark Diagnostics said Thursday that it has achieved CE marking under the European In‐Vitro Diagnostic Devices Directive for its ePlex Blood Culture Identification fungal pathogen panel.

The panel is the first in the GenMark Sepsis Solution, which will also include BCID Gram-Positive and Gram-Negative panels, the firm said.

"Rapid diagnosis of bloodstream infections can have significant impact on improving patient outcomes and reducing cost of therapy," Hany Massarany, president and CEO of GenMark, said in a statement, adding GenMark's approach will enable this impact by providing "the broadest pathogen inclusivity and drug resistance markers of any multiplex molecular solution on the market today."

Danièle Maubon, a clinician at the Grenoble Alpes University Hospital, said that "fungal bloodstream infections are some of the most critical conditions we face in the clinical laboratory, and diagnosing them quickly and accurately has a significant positive impact on patient outcomes."

Maubon noted that the ePlex Fungal Pathogen Panel brings rapid and essential information regarding fungemia, and its ease of use "allows a perfect integration in the routine workflow."

GenMark also reported preliminary first quarter 2017 revenues of $12.5 million, an increase of 13 percent over the prior-year period. The firm said that it added more than 15 customer agreements during Q1, and that it finished the first quarter with more than 70 agreements for more than 100 ePlex analyzers, many of which have been installed at end-user sites.

Massarany said that first quarter revenue was in line with its expectations.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.